Market Cap: $142.15M
AI
Atrium Therapeutics, Inc.
RNA
NASDAQ (NASDAQ Global Select)USD
Market Cap: $142.15M
Avidity Biosciences Gears Up for Strategic Merger and Stock Distribution Avidity Biosciences, Inc. announces a pivotal update regarding its special meeting of stockholders, originally set for February…
Avidity Biosciences Advances Towards Major Merger and Stock Distribution Avidity Biosciences, Inc. confirms its commitment to enhancing shareholder value through a strategic merger with Novartis AG an…
Objective molecular readouts for spinal cord stimulation take shape PROVIDENCE/ DAYTON — Lilac Biosciences and Soin Neuroscience are launching a preclinical collaboration to test whether RNA expressio…
RNA readouts aim to objectify pain response Lilac Biosciences is partnering with Soin Neuroscience to test whether changes in RNA expression can serve as reproducible molecular signatures of response…
AOC brain-delivery push signals industry shift Aerska is advancing antibody‑oligonucleotide conjugates (AOCs) with a "brain shuttle" designed to overcome the blood–brain barrier, a move that reshapes…
AOC SHIFT TO CNS SIGNALS PLATFORM VALIDATION Aerska’s recent Series A financing for its antibody‑oligonucleotide conjugate (AOC) platform is sharpening industry attention on AOC technology and its pot…
Aerska’s brain-shuttle advance aims to unlock systemic RNAi for the brain Aerska raises $39 million in a Series A round led by EQT Life Sciences’ LSP Dementia Fund and age1 to propel its antibody‑olig…
Atrium Spin‑Off Record Date Tied to Novartis Deal Avidity Biosciences says its board sets the close of business Eastern Time on Feb. 12, 2026 as the record date for a pro rata distribution of shares i…
Avidity sets Feb. 12 record date for Atrium spin-off Avidity Biosciences names the close of business Eastern Time on Feb. 12, 2026 as the record date for a pro rata distribution of shares in Atrium Th…
Board sets Feb. 12 record date for Atrium distribution as part of Novartis deal Avidity Biosciences says its board designates the close of business Eastern Time on Feb. 12, 2026 as the record date for…
Advancing Oligonucleotide Therapeutics: Insights from a Recent Webinar In a pivotal webinar hosted by Rockland Immunochemicals, industry professionals delve into universal detection strategies essenti…
Advancements in RNA Modification Research: STORM Therapeutics and Alida Biosciences Join Forces STORM Therapeutics Ltd. recently announces a pivotal collaboration with Alida Biosciences Inc., focusing…
A New Era in RNA Therapeutics: STORM and AlidaBio Collaborate on METTL3 Inhibition In a significant advancement for RNA-based therapeutics, STORM Therapeutics Ltd. announces a strategic collaboration…
Circular Genomics Relocates to Foster Innovations in Alzheimer's Diagnostics Circular Genomics, a pioneering company specializing in circular RNA (circRNA) biomarkers for precision neurology and psych…
Circular Genomics Relocates to Enhance Alzheimer's Diagnostics Development Circular Genomics, a pioneer in circular RNA (circRNA) biomarkers, announces its relocation to Lilly Gateway Labs in San Dieg…
Strategic Alliance to Revolutionize RNA Therapies Avidity Biosciences is at the forefront of a transformative shift in the biotechnology landscape, particularly in the realm of RNA therapies. A recent…
Orna Therapeutics and Simnova Collaborate on BCMA-Targeted RNA Therapeutics Orna Therapeutics, Inc. has recently expanded its strategic collaboration with Shanghai Simnova Biotech Co., Ltd. to include…
Revolutionizing RNA Therapeutics: Keylicon Biosciences' Breakthrough Collaboration In a significant development for RNA therapeutic technologies, Keylicon Biosciences has secured exclusive rights to a…
Pioneering Predictive Solutions in Pregnancy Health Mirvie, a South San Francisco-based biotechnology company, is at the forefront of revolutionizing maternal-fetal health through its innovative RNA p…
New Insights into RNA Fragments Offer Hope for Cancer Treatment A recent study published in Nature Communications sheds light on the role of a specific transfer RNA-derived fragment, 5'-tRNAGly(GCC),…
Emerging RNA Therapeutics: A Focus on 5'-tRNAGly(GCC) in Cancer Treatment A recent study led by Professor Kangseok Lee from Chung-Ang University uncovers the pivotal role of 5'-tRNAGly(GCC) in gene ex…
Innovative Advances in RNA-Targeted Treatments for Myotonic Dystrophy Arrakis Therapeutics, a biopharmaceutical company located in Waltham, Massachusetts, presents groundbreaking preclinical data conc…
Shifting Paradigms in Genetic Research: Implications for Avidity Biosciences Recent advancements in the understanding of genetics and molecular biology signal a significant shift from the traditional…
Cofactor Genomics Launches Groundbreaking Diagnostic Tool for Non-Small Cell Lung Cancer Cofactor Genomics, Inc., a pioneer in RNA-based precision medicine, recently announces the launch of its novel…
Revolutionizing mRNA Production: NTx's NTxscribe System Set for Industry Debut Nature’s Toolbox (NTx), a life sciences innovator based in Rio Rancho, New Mexico, is gearing up to unveil its cutting-ed…